Monopar Therapeutics Stock (NASDAQ:MNPR)
Previous Close
$4.85
52W Range
$1.37 - $8.65
50D Avg
$3.35
200D Avg
$3.23
Market Cap
$16.02M
Avg Vol (3M)
$824.86K
Beta
1.26
Div Yield
-
MNPR Company Profile
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
MNPR Performance
Peer Comparison
Ticker | Company |
---|---|
ENOB | Renovaro Biosciences Inc. |
PMVP | PMV Pharmaceuticals, Inc. |
MLYS | Mineralys Therapeutics, Inc. |
SCPH | scPharmaceuticals Inc. |
KTTA | Pasithea Therapeutics Corp. |
AVTE | Aerovate Therapeutics, Inc. |
ACRV | Acrivon Therapeutics, Inc. Common Stock |
ACXP | Acurx Pharmaceuticals, Inc. |
SCPS | Scopus BioPharma Inc. |
ANTX | AN2 Therapeutics, Inc. |
PHVS | Pharvaris N.V. |
RZLT | Rezolute, Inc. |
DMAC | DiaMedica Therapeutics Inc. |
CADL | Candel Therapeutics, Inc. |
PEPG | PepGen Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
ADAG | Adagene Inc. |
MOLN | Molecular Partners AG |